MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Exelixis Inc

Открыт

СекторЗдравоохранение

37.08 -0.7

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

36.6

Макс.

37.4

Ключевые показатели

By Trading Economics

Доход

140M

Продажи

27M

567M

P/E

Средняя по отрасли

20.727

57.333

Прибыль на акцию

0.55

Рентабельность продаж

24.678

Сотрудники

1,147

EBITDA

171M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+1.93% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

29 апр. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

756M

10B

Предыдущая цена открытия

37.78

Предыдущая цена закрытия

37.08

Техническая оценка

By Trading Central

Уверенность

Very Strong Bullish Evidence

Exelixis Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 апр. 2025 г., 23:54 UTC

Популярные акции

Stocks to Watch: Alphabet, Intel, AppFolio

24 апр. 2025 г., 23:51 UTC

Обсуждения рынка

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 апр. 2025 г., 23:46 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

24 апр. 2025 г., 23:46 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 апр. 2025 г., 23:37 UTC

Главные новости

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 апр. 2025 г., 23:36 UTC

Главные новости

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 апр. 2025 г., 23:13 UTC

Главные новости
Отчет

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 апр. 2025 г., 23:09 UTC

Главные новости

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 апр. 2025 г., 23:02 UTC

Приобретения, слияния, поглощения

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 апр. 2025 г., 23:02 UTC

Приобретения, слияния, поглощения

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 апр. 2025 г., 22:51 UTC

Главные новости
Приобретения, слияния, поглощения

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 апр. 2025 г., 22:48 UTC

Главные новости

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 апр. 2025 г., 22:47 UTC

Обсуждения рынка

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 апр. 2025 г., 22:38 UTC

Обсуждения рынка
Отчет

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 апр. 2025 г., 22:24 UTC

Отчет

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 апр. 2025 г., 22:24 UTC

Отчет

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 апр. 2025 г., 22:24 UTC

Обсуждения рынка
Отчет

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 апр. 2025 г., 22:23 UTC

Отчет

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 апр. 2025 г., 22:11 UTC

Обсуждения рынка
Отчет

Global Equities Roundup: Market Talk

24 апр. 2025 г., 22:11 UTC

Обсуждения рынка
Отчет

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 апр. 2025 г., 22:09 UTC

Главные новости
Отчет

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 апр. 2025 г., 22:00 UTC

Обсуждения рынка
Отчет

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 апр. 2025 г., 21:39 UTC

Главные новости

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 апр. 2025 г., 21:24 UTC

Главные новости
Отчет

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 апр. 2025 г., 21:24 UTC

Главные новости
Отчет

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 апр. 2025 г., 21:23 UTC

Главные новости
Отчет

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 апр. 2025 г., 21:04 UTC

Отчет

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 апр. 2025 г., 21:03 UTC

Отчет

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 апр. 2025 г., 21:03 UTC

Отчет

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 апр. 2025 г., 21:02 UTC

Отчет

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Сравнение c конкурентами

Изменение цены

Exelixis Inc Прогноз

Целевая цена

By TipRanks

1.93% рост

Прогноз на 12 месяцев

Средняя 37.93 USD  1.93%

Максимум 45 USD

Минимум 29 USD

Основано на мнении 15 аналитиков Wall Street, спрогнозировавших целевые цены для Exelixis Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

15 ratings

9

Покупка

6

Удержание

0

Продажа

Техническая оценка

By Trading Central

36.54 / 37.67Поддержка и Сопротивление

Краткосрочная

Very Strong Bullish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Weak Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.